Current status of intensive end-of-life care in children with hematologic malignancy: a population-based study

Nobuyuki Yotani1, Daisuke Shinjo2, Motohiro Kato3

  • 1Department of Palliative Medicine, National Centre for Child Health and Development, 2-10-1, Okura, Setagaya-ku, Tokyo, Japan. yotani-n@ncchd.go.jp.

BMC Palliative Care
|June 8, 2021
PubMed

Insights

Children with hematologic malignancies receive more intensive end-of-life care (EOLC) than those with solid tumors. Younger age and shorter hospital stays are linked to intensive EOLC in these pediatric patients.

Area of Science:

  • Pediatric Oncology
  • Palliative Care Research
  • Hematologic Malignancies

Background:

  • Limited data exist on end-of-life care (EOLC) quality for children with hematologic malignancies.
  • Adults with hematologic malignancies receive less palliative care and more intensive treatments near end-of-life compared to solid tumor patients.

Purpose of the Study:

  • Compare intensive EOLC between pediatric hematologic malignancy and solid tumor patients.
  • Identify factors associated with intensive EOLC in children with hematologic malignancies.

Main Methods:

  • Retrospective review of pediatric cancer patients (0-18 years) who died in hospital in Japan (2012-2016).
  • Defined intensive EOLC indicators: ICU admission, CPR, ventilation, dialysis, ECMO (last 30 days), or chemotherapy (last 14 days).
  • Used regression models to determine factors associated with intensive EOLC.

Main Results:

  • Children with hematologic malignancies (36%) received significantly more intensive EOLC (ICU admission, CPR, ventilation, dialysis, ECMO, chemotherapy) than solid tumor patients.
  • Over 90% of children with hematologic malignancies received blood transfusions in the last 7 days of life.
  • Younger age (<5 years) and shorter hospital stays were associated with intensive EOLC in hematologic malignancy patients.

Conclusions:

  • Pediatric patients with hematologic malignancies are more likely to receive intensive end-of-life care compared to those with solid tumors.
  • Younger age and shorter hospital stays may be associated with receiving intensive EOLC in children with hematologic malignancies.
Abstract

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
601
Continuing Care01:25

Continuing Care

Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.6K
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
7.4K